Literature DB >> 23955637

Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.

A H E Herbers1, W J F M van der Velden1, A F J de Haan2, J P Donnelly1, N M A Blijlevens1.   

Abstract

The matched-control study failed to show a clinical relevant impact of palifermin on intestinal mucositis, although there was a reduced inflammatory response and less febrile neutropenia among patients who had no bacteraemia.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23955637     DOI： 10.1038/bmt.2013.118

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  16 in total

1.  Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice.

Authors:  C Barazzone; Y R Donati; A F Rochat; C Vesin; C D Kan; J C Pache; P F Piguet
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

2.  Colonization and molecular epidemiology of coagulase-negative Staphylococcal bacteremia in cancer patients: a pilot study.

Authors:  Silvia F Costa; Antonio A Barone; Marisa H Miceli; Inneke M van der Heijden; Robson E Soares; Anna S Levin; Elias J Anaissie
Journal:  Am J Infect Control       Date:  2006-02       Impact factor: 2.918

3.  Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.

Authors:  J D Goldberg; J Zheng; H Castro-Malaspina; A A Jakubowski; G Heller; M R M van den Brink; M-A Perales
Journal:  Bone Marrow Transplant       Date:  2012-07-02       Impact factor: 5.483

4.  Palifermin induces alveolar maintenance programs in emphysematous mice.

Authors:  Ali O Yildirim; Vandana Muyal; Gerrit John; Bernd Müller; Carola Seifart; Michael Kasper; Heinz Fehrenbach
Journal:  Am J Respir Crit Care Med       Date:  2009-12-10       Impact factor: 21.405

5.  In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.

Authors:  N Blijlevens; M de Château; G Krivan; W Rabitsch; A Szomor; R Pytlik; A Lissmats; H E Johnsen; T de Witte; H Einsele; T Ruutu; D Niederwieser
Journal:  Bone Marrow Transplant       Date:  2012-12-17       Impact factor: 5.483

6.  Gut protection by palifermin during autologous haematopoietic SCT.

Authors:  J-E Johansson; B Hasséus; P Johansson; C Eklöf; D Ohman; D Stockelberg
Journal:  Bone Marrow Transplant       Date:  2008-12-01       Impact factor: 5.483

7.  Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients.

Authors:  A H E Herbers; N M A Blijlevens; J P Donnelly; T J M de Witte
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

8.  Febrile mucositis in haematopoietic SCT recipients.

Authors:  W J F M van der Velden; N M A Blijlevens; T Feuth; J P Donnelly
Journal:  Bone Marrow Transplant       Date:  2008-09-01       Impact factor: 5.483

9.  Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.

Authors:  B E De Pauw; S C Deresinski; R Feld; E F Lane-Allman; J P Donnelly
Journal:  Ann Intern Med       Date:  1994-05-15       Impact factor: 25.391

10.  The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies.

Authors:  T J Ruescher; A Sodeifi; S J Scrivani; L B Kaban; S T Sonis
Journal:  Cancer       Date:  1998-06-01       Impact factor: 6.860
View more
  5 in total

1.  Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.

Authors:  Joanne M Bowen; Rachel J Gibson; Janet K Coller; Nicole Blijlevens; Paolo Bossi; Noor Al-Dasooqi; Emma H Bateman; Karen Chiang; Charlotte de Mooij; Bronwen Mayo; Andrea M Stringer; Wim Tissing; Hannah R Wardill; Ysabella Z A van Sebille; Vinisha Ranna; Anusha Vaddi; Dorothy Mk Keefe; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad
Journal:  Support Care Cancer       Date:  2019-07-08       Impact factor: 3.603

2.  Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.

Authors:  Per Boye Hansen; Milena Penkowa
Journal:  Support Care Cancer       Date:  2016-12-13       Impact factor: 3.603

3.  Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.

Authors:  G Milone; S Leotta; A Cupri; A L Fauci; P Spina; M Parisi; D Berritta; G Tripepi
Journal:  Bone Marrow Transplant       Date:  2014-07-07       Impact factor: 5.483

4.  Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation.

Authors:  Elvio G Russi; Judith E Raber-Durlacher; Stephen T Sonis
Journal:  Mediators Inflamm       Date:  2014-03-16       Impact factor: 4.711

5.  Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)-study protocol for a multicenter randomized double-blind placebo-controlled trial.

Authors:  Charlotte E M de Mooij; Lenneke F J van Groningen; Anton F J de Haan; Bart J Biemond; Martijn Bakker; Walter J F M van der Velden; Nicole M A Blijlevens
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.